Articles
11 June 2009
Vol. 3 No. 1: 2006...2009: Now we know T-cell lymphomas better, Bologna, Italy, 16-18 March 2009
https://doi.org/10.4081/hmr.v3i1.527

Activity of Belinostat in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
264
Views
349
Downloads

Authors

F Foss
support@pagepress.org
R Advani
K Hymes
B Pohlman
E Jacobsen
J McDonnell
A Lerner
Belinostat (PXD101) is a hydroxamate pan HDAC inhibitor which demonstrates broad antineoplastic activity in vitro and in vivo. Phase I studies have shown that belinostat is well-tolerated and has had activity in T-cell malignancies.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Activity of Belinostat in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 3(1). https://doi.org/10.4081/hmr.v3i1.527